Sponsors & CROs
Partner With PsychPlus
A scalable nationwide clinical research network built around psychiatric expertise, patient-centered care, and broad access to diverse patient populations.
PsychPlus partners with pharmaceutical and biotechnology companies, contract research organizations, academic institutions, and research organizations to support clinical research across psychiatry, neuroscience, and other CNS conditions.
A Nationwide Research Network
Scale and reach across the United States, with centralized research leadership coordinating research partnerships.
Operating in All 50 States
1,000+
Providers
275+
Facilities & Clinics
Research Capabilities
Feasibility
Protocol feasibility and patient population assessment to help evaluate study opportunities across our network.
Sites & Investigators
Identification and coordination of appropriate clinical locations and investigators based on study requirements.
Patient Recruitment
Patient population identification and recruitment planning, subject to applicable privacy and regulatory requirements.
Study Start-Up
Centralized coordination to support regulatory processes, site readiness, staffing, and study initiation.
Study Operations
Multi-site operational coordination, standardized procedures, quality oversight, enrollment support, and performance tracking.
Centralized Partnership
A single point of contact for coordinating research opportunities across the PsychPlus network.
Why Partner With PsychPlus?
Diverse Patient Access
Our network supports broad and diverse patient populations across multiple geographic markets and psychiatric indications.
Psychiatric Expertise
PsychPlus providers bring clinical expertise across common and complex psychiatric conditions.
Scalable Site Selection
Evaluate appropriate investigators and locations through one centralized clinical research team.
Technology-Enabled Feasibility
Data-informed feasibility assessments and patient identification strategies, subject to applicable privacy and regulatory requirements.
Community-Based Research
Bring clinical research opportunities closer to the communities where patients already receive care.
Clinical Research Focus Areas
A broad CNS portfolio spanning psychiatry and neuroscience, supported by experienced providers across our nationwide network.
Psychiatry
Major Depressive Disorder
Treatment-Resistant Depression
Bipolar Disorder
Schizophrenia & Psychosis
Post-Traumatic Stress Disorder
Anxiety Disorders
ADHD
Neurology & CNS
Alzheimer’s Disease & Dementia
Parkinson’s Disease
Epilepsy
Migraine
Multiple Sclerosis
Additional Research Areas
Autism Spectrum Disorder
Sleep Disorders
Substance Use Disorders
Other Psychiatry & CNS Conditions
Phases of Clinical Research Expertise
PsychPlus supports Phase I through Phase IV clinical research, with a primary focus on psychiatry, behavioral health, neuroscience, and central nervous system (CNS) disorders.
Through our national mental health network, which serves patients across all 50 states, PsychPlus provides sponsors and CROs with access to experienced psychiatric investigators, established clinical locations, and a large, diverse patient population representing a broad range of demographic, geographic, and clinical backgrounds.
Our research capabilities are well suited for studies involving major depressive disorder, treatment-resistant depression, anxiety disorders, PTSD, ADHD, bipolar disorder, schizophrenia, Alzheimer’s-related neuropsychiatric symptoms, and other CNS indications.
Phase I – Early Clinical Development
PsychPlus supports selected Phase I and early-phase psychiatric and CNS studies when protocol requirements align with site capabilities.
These studies may include intensive clinical assessments, safety monitoring, pharmacokinetic or pharmacodynamic procedures, investigational product management, and protocol-specific clinical oversight. Each opportunity is evaluated based on investigator qualifications, participant safety requirements, infrastructure, and operational readiness.
Phase II – Proof of Concept and Dose Evaluation
PsychPlus supports Phase II studies evaluating preliminary efficacy, safety, tolerability, dose response, and clinical outcomes in psychiatric and CNS populations.
Our combination of experienced investigators, broad patient access, and dedicated mental health clinical settings supports efficient feasibility assessment, participant identification, recruitment, and protocol execution.
Phase III – Large-Scale Clinical Trials
PsychPlus supports Phase III psychiatric and CNS studies requiring larger patient populations, structured recruitment, standardized psychiatric assessments, consistent protocol execution, and coordinated multi-site oversight.
Our national clinical reach enables protocol feasibility assessments across multiple geographic regions and supports identification of appropriate investigators, clinical locations, and potential patient populations based on study-specific requirements.
Phase IV – Post-Marketing and Real-World Research
PsychPlus supports Phase IV, observational, post-marketing, and real-world evidence studies designed to evaluate long-term safety, treatment effectiveness, patient outcomes, treatment patterns, and the use of approved therapies in routine psychiatric practice.
Our national mental health network and access to diverse patient populations provide a strong foundation for real-world research across varied geographic regions, patient groups, and clinical care settings.
Frequently Asked Questions
Lets Discuss Your Clinical Research Opportunity
PsychPlus welcomes opportunities to partner with pharmaceutical and biotechnology companies, CROs, academic institutions, and research organizations seeking qualified clinical research sites and investigators.
Our clinical research network supports study feasibility, investigator identification, site selection, patient recruitment, site activation, and high-quality study execution across psychiatry, neuroscience, and related therapeutic areas.
Whether you are evaluating sites for an upcoming protocol or expanding an existing clinical trial, our team is available to discuss site capabilities, patient population, investigator experience, and study feasibility.
For clinical trial opportunities, feasibility assessments, and site partnership inquiries, please contact:
[email protected]